SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-17-010533
Filing Date
2017-11-01
Accepted
2017-11-01 17:15:21
Documents
54
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20170930x10q.htm 10-Q 760977
2 EXHIBIT 31.1 mrtx93017ex311.htm EX-31.1 12408
3 EXHIBIT 31.2 mrtx93017ex312.htm EX-31.2 12872
4 EXHIBIT 32.1 mrtx93017ex321.htm EX-32.1 8237
  Complete submission text file 0001628280-17-010533.txt   3273290

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT mrtx-20170930.xml EX-101.INS 666561
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20170930.xsd EX-101.SCH 24218
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20170930_cal.xml EX-101.CAL 46285
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20170930_def.xml EX-101.DEF 78331
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20170930_lab.xml EX-101.LAB 297682
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20170930_pre.xml EX-101.PRE 167565
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 171169881
SIC: 2834 Pharmaceutical Preparations